AMT-260

N/A

Report date: 2024/11/25 16:42:33

Base Information

Drug NameAMT-260
Drug Alias NameAAV9-hSyn1-miGRIK2AMT-260
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV9 vector
Mechanisms of ActionRNA interferenceKainic acid receptor antagonistsGlutamate receptor ionotropic, kainate 2 modulators
TargetsKainic acid receptorGlutamate receptor ionotropic, kainate 2
Therapy Area/IndicationsEpilepsy, Temporal Lobe
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniqure NvCorlieve Therapeutics SAS
China Registration ClassN/A

Develop Information

Active CompaniesUniqure NvUniqure Biopharma Bv
Inactive CompaniesN/A
Active IndicationsEpilepsy, Temporal Lobe
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A